OncoSec to Host Investor & Analyst Day on November 17, 2016 Spotlighting Industry-Leading Intratumoral Immunotherapy Pipeline and Next Generation Research and Device Development
SAN DIEGO, Oct. 18, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it will be holding its inaugural Investor & Analyst Day on November 17th in San Diego, where the Company will share updates on its clinical development plan for melanoma, advancement on its intratumoral immunotherapy pipeline of DNA-based product candidates, and next generation research and device development. The event will be webcast live via video stream beginning at 9:00 AM Pacific Time, and will be available through the Events section under the Investors tab of OncoSec's website at www.oncosec.com. The webcast will also be available for replay on the Company website. The approximately two-hour agenda for the Investor & Analyst Day is intended to provide a comprehensive overview of OncoSec. Presentations will be made by Key Opinion Leaders in the Immuno-Oncology field, collaborators, and OncoSec's management team. The presentations will focus on the following areas:
The Company will distribute additional details in subsequent communications. About OncoSec Medical Incorporated CONTACT: Logo - http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-host-investor--analyst-day-on-november-17-2016-spotlighting-industry-leading-intratumoral-immunotherapy-pipeline-and-next-generation-research-and-device-development-300346374.html SOURCE OncoSec Medical Incorporated |
|